Canopy Growth Corporation - Common Shares (NQ:CGC)

Canopy Growth Announces Results of 2026 Annual General and Special Meeting of Shareholders

October 26, 2026

Performance

52-Week Range 68.7% below 52-week high

0.7445

0.6452W Low 2.3852W High

1 Week

0.641W Low 0.741W High

Canopy Growth Corporation - Common Shares (CGC) traded between $0.64 and $2.38 over the past 52 weeks and last traded at $0.74, 68.7% below its 52-week high. Over the past week it ranged between $0.64 and $0.74.

Past 12 Months

+10.8%

-15.8%

-20.1%

-31.1%

-37.4%

-38.0%

1W +$0.07

1M -$0.14

3M -$0.19

6M -$0.34

YTD -$0.45

1Y -$0.46

CGC was -38.0% over the past year, -31.1% over six months, -37.4% year to date, +10.8% in the last week.

12 Months vs Market

CGC

-38.0%

DIA

+12.6%

SPY

+12.4%

QQQ

+9.9%

IWM

+15.7%

Over the past 12 months CGC returned -38.0% versus DIA (Dow) +12.6%, SPY (S&P 500) +12.4%, QQQ (Nasdaq 100) +9.9% and IWM (Russell 2000) +15.7%.

Volume & Liquidity 0.76× 3-mo avg

Today 2,176,232 3-mo avg 2.9M

1.9M

2.4M

2.9M

4.1M

YTD

7.2M

12.2M

CGC most recently traded 2,176,232 shares against a 3-month average daily volume of 2.9M.

More News

Canopy Growth Shareholders Approve Reverse Split Authority, Elect Board ↗

October 23, 2026

Via MarketBeat

Canopy Growth to Report Second Quarter Fiscal 2027 Financial Results on November 6, 2026

October 22, 2026

Trump's Marijuana Order Is Stuck at the DEA. Here's What That Means for Canopy Growth. ↗

October 18, 2026

Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026? ↗

October 15, 2026

Canopy Growth’s Smiths Falls Facility Becomes Canada’s Only EU GMP-Certified Site Combining Softgel Manufacturing With Primary Packaging of Softgels, Oral Liquids and Dried Cannabis Flower

October 13, 2026

Canopy Growth vs. Tilray Brands: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 10, 2026

Can Canopy Growth Survive Another 5 Years? ↗

October 06, 2026

Canopy Growth Is Closing in on Positive EBITDA. Should You Buy the Stock? ↗

September 30, 2026

Canopy Growth Appoints Sebastian Blöte as Country Manager for Germany

September 28, 2026

Canopy Growth Announces Adjournment of 2026 Annual General and Special Meeting Due to Lack of Quorum

September 25, 2026

Canopy Growth Is Eyeing Another Reverse Stock Split. Will It Be Enough to Light a Fire Beneath the Beaten-Down Pot Stock? ↗

September 23, 2026

Canopy Growth Announces Extension of Proxy Voting Deadline for 2026 Annual General and Special Meeting

September 23, 2026

Canopy Growth Expands European Medical Cannabis Supply Into the UK

September 22, 2026

Canopy Growth's Business Is Improving. So Why Isn't the Stock Performing Better? ↗

September 14, 2026

Canopy Growth Reminds Shareholders to Vote Ahead of September 23 Deadline

September 14, 2026

Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations

September 08, 2026

Canopy Growth's Revenue Grew 13% Last Quarter. Investors Barely Reacted. Here's Why. ↗

September 07, 2026

Should You Buy Canopy Growth Stock on the Rebound? ↗

September 05, 2026

Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands? ↗

September 02, 2026

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners. ↗

August 21, 2026

Canopy Growth Announces Mailing of Proxy Materials for 2026 Annual General and Special Meeting – Urges Shareholders to Vote Now

August 17, 2026

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target? ↗

August 16, 2026

Canopy Growth (CGC) Q1 2027 Earnings Call Transcript ↗

August 14, 2026